Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
bit.bio
Cambridge, England, United Kingdombit.bio ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Preclinical
01
Overview
bit.bio has demonstrated the ability to produce highly defined human iPSC-derived cells at scale with precision and consistency using its opti‑ox™ platform. These products are commercially available as ioCells™ for research and drug discovery. The company claims its technology will enable next-generation cell therapies but has not yet reported clinical results or advanced programs into clinical trials as of May 2025
- Therapeutic areas
- OtherNeurology
- Modalities
- iPSC-derived cells (induced pluripotent stem cell-derived cells)Engineered human cell models for research and drug discoveryPotential future cell therapies
- Industry
- Non-Drug Biotech
02
Partnerships
Academic collaborations via Milner Therapeutics InstitutePartnerships with pharma/biotech companies not specifically named but implied through investor base and board connections
Beyond the preview
Go deeper on bit.bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bit.bio.